The biological basis of disease recurrence in psoriasis: a historical perspective and current models
Top Cited Papers
Open Access
- 2 May 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (5) , 773-781
Abstract
A key challenge in psoriasis therapy is the tendency for lesion recurrence in previously affected anatomical locations after treatment discontinuation following lesion resolution. Available evidence supports the concept of a localized immunological ‘memory’ that persists in resolved skin after complete disappearance of visible inflammation, as well as the role of a specific subpopulation of T cells characterized by the dermotropic CCR4+ phenotype and forming a local memory. Increasing knowledge of the interleukin (IL)-23/T-helper cell (Th)17 pathway in psoriasis immunopathology is pointing away from the historical classification of psoriasis as primarily a Th1-type disease. Research undertaken from the 1990s to the mid-2000s provided evidence for the existence of a large population of CD8+ and CD4+ tissue-resident memory T cells (TRMs) in resolved skin, which can initiate and perpetuate immune responses of psoriasis in the absence of T-cell recruitment from the blood. Dendritic cells (DCs) are antigen-presenting cells that contribute to psoriasis pathology via the secretion of IL-23, the upstream regulator of Th17 cells, while plasmacytoid DCs are involved via IL-36 signalling and type I interferon activation. Overall, the evidence discussed in this review indicates that IL-23 driven/IL-17-producing T cells play a critical role in psoriasis pathology and recurrence, which make these cytokines logical therapeutic targets. The review also explains the clinical efficacy of IL-17 and IL-23 receptor blockers in the treatment of psoriasis.Keywords
This publication has 94 references indexed in Scilit:
- Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunityNature Genetics, 2012
- Interleukin-17C Promotes Th17 Cell Responses and Autoimmune Disease via Interleukin-17 Receptor EImmunity, 2011
- Resolved Psoriasis Lesions Retain Expression of a Subset of Disease-Related GenesJournal of Investigative Dermatology, 2011
- Circulating Th17, Th22, and Th1 Cells Are Increased in PsoriasisJournal of Investigative Dermatology, 2010
- Cytokine-Producing Dendritic Cells in the Pathogenesis of Inflammatory Skin DiseasesJournal of Clinical Immunology, 2009
- The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivoNature Immunology, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesJournal of Experimental Medicine, 2007
- Development, cytokine profile and function of human interleukin 17–producing helper T cellsNature Immunology, 2007
- Prevalence and Treatment of Psoriasis in the United KingdomArchives of Dermatology, 2005